FSHD is caused by the loss of repression at the D4Z4 locus leading to aberrant DUX4 expression in skeletal muscle, activation of its early embryo transcriptional program and muscle fiber death. • While some progress toward understanding the signals driving DUX4 expression has been made, the factors and pathways involved in the transcriptional activation of this gene remain largely unknown. • Using optimized myotube culture conditions, we identified p38 MAPK as a key regulator of DUX4 expression. • We observed that treatment with the p38α/β inhibitor losmapimod results in reduction of DUX4 expression, activity and cell death in FSHD patient-derived myotubes with minimal impact on myogenesis. • RNA-seq studies revealed that only a small number of genes were differentially expressed after treatment with losmapimod, ~90% of these are targets of DUX4. • Fulcrum Therapeutics has selected losmapimod, a specific p38α/β inhibitor, for clinical development in FSHD.
Facioscapulohumeral Muscular Dystrophy (FSHD)
(A) Schematic of the loss in gene repression caused by contraction of D4Z4 repeats that leads to DUX4 expression in the muscle of FSHD1 patients. (B) Schematic describing the downstream consequences of DUX4 expression in skeletal muscle.
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Fulcrum's approach to target identification and validation
Cell-based screening drives Fulcrum's target identification engine 
Identification of a drug target that inhibits DUX4 expression

Losmapimod reduces DUX4 activation and its downstream consequences (A)
Losmapimod treatment does not affect in vitro differentiation of myotubes. (B) RNA-seq analysis of myotubes indicates that losmapimod selectively inhibits DUX4 and its downstream program expression in a concentration dependent manner with minimal impact across the transcriptome of FHSD myotubes. <100 differentially expressed genes (abs(FC)>4; FDR<0.001) (C) Losmapimod reduces cleaved caspase-3 signal detected in FSHD myotubes indicating reduction of cell death. 
DUX4 activity and apoptosis in primary myotubes
Conclusions
• Using an in vitro model of FSHD, we identify novel regulators of aberrant DUX4 expression.
• Losmapimod is a selective p38α/β inhibitor that reduces DUX4 expression in FSHD myotubes.
• Further in vitro characterization demonstrates that the DUX4-driven gene expression and cell death are inhibited in FSHD myotubes exposed to losmapimod. 
